CORDIS · 101167102 · HORIZON
Custom-Made CUSTOM-MADE NEURONS FOR CELL THERAPY IN PARKINSON’S AND HUNTINGTON’S DISEASE
Coordinator: UNIVERSITA DEGLI STUDI DI MILANO (IT)
The rising incidence of age-associated neurodegenerative diseases, due to increased life expectancy, poses a challenge to the brain's limited regenerative capabilities. Stem cell-based therapies offer promise for addressing crucial neuron loss, particularly in Parkinson’s and Huntington’s diseases (PD and HD). Ongoing first-generation stem cell trials, replacing damaged neurons with healthy ones, represent a notable advancement. However, their impact is constrained by a ‘one-cell-fits-all’ generic therapy that does not take in account the diverse clinical needs due to variations in disease et…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €10.0M awarded to the consortium. The project runs over approximately 6 years from 2025-11-01 to 2031-10-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IT
see all →- THCS — European Partnership on Transforming Health and Care Systems101095654 · HORIZON · €91.6M
- c4c — conect4children (COllaborative Network for European Clinical Trials For Children)777389 · H2020 · €67.0M
- ADITEC — Advanced Immunization Technologies280873 · FP7 · €30.0M
- ARCHETYPE SW550 — Demonstration of innovating parabolic solar trough using an alternative heat transfer fluid producing electricity and fresh water: ARChimede Hot Energy TYPology Enhanced Water Solar 550268181 · FP7 · €29.7M
- EPOS IP — EPOS Implementation Phase676564 · H2020 · €18.4M
- COMETHA — 80,000 TON/Y PRECOMMERCIAL INDUSTRIAL SCALE DEMONSTRATION PLANT ON SECOND GENERATION LIGNOCELLULOSIC ETHANOL322406 · FP7 · €17.9M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-ERC-SYG funding scheme.
- What is the EU contribution?
- The European Commission contributes €10.0M toward a total project budget of €10.0M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call ERC-2024-SyG.
- Who coordinates the project?
- The project is coordinated by UNIVERSITA DEGLI STUDI DI MILANO (IT).
- What is the project timeline?
- The project runs from 2025-11-01 to 2031-10-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101167102.